Menu
Company Information
Company Name
CUePEAK BIO. Co.,Ltd.
Founding Date
Mar. 3, 2020
Location
KRIBB* Bioventure center, Korea (Head Office)
*KRIBB: Korea Research Institute of Bioscience and Biotechnology, the only government-funded research institute in the field of biotechnology
Financials
Investment: 130,000,000 Yen
National R&D Expenses: 200,000,000 Yen
Funding (to be raised): 500,000,000 Yen
Patent Holding
Total 33
Specialties & Interests
Skin and Hair Disease over 20+ years of experience in research in new drug development
Precision Medicine customized medicine and companion diagnosis
Innovative drug development and drug repositioning
Experience
Ph.D. (2001) University of Tsukuba, JAPAN
JSPS Fellow (2001-2003) National Institute of Advanced Industrial Science and Technology (AIST), METI, JAPAN
US NIH Fellow (2003-2011) National Institutes of Health
(NIH/NIAMS), DHHS, USA
Principal Investigator (2011-Present) Korea Research Institute of Bioscience and Biotechnology, KOREA
Achievements
40+ publications including Nature Cell Biology and PNAS
30+ patents
Core products
Precision Medicine for Atopic dermatitis : Customized Medicine + Companion Diagnosis
Customized Medicine CP001
[Targent Patients] Atopic Dermatitis (AD) patients with Filaggrin abnormalities
[MOA] increase Filaggrin (FLG) expression and recover skin barrier function
[Drug Repositioning] ensure drug safety, increase development speed and success rate
[Preventive Medicine] identify potential AD patients by IVD allowing for early preventive treatments, leading to lower incidence rates of AD, and reducing total healthcare expenses
[3rd Generation Medicine] overcoming the side effects of existing topical (non)corticosteroids
[PoC verification in vivo] recovery of skin barrier function due to increase in filaggrin expression
Companion Diagnosis (in vitro diagnostics : IVD)
[in vitro diagnostics] detect genetic abnormalities in Filaggrin gene from Atopic Dermatitis patients
[Prenatal Diagnosis] detect Filaggrin mutations in newborns, infants, and toddlers who has a particularly high incidence rate for AD
[Innovative] Probe-based FMCA (Fluorescence Melting Curve Analysis) method allows a convenient, rapid and accurate diagnostic tool, providing a high-throughput method to reliable screen AD patients
[Publication] “Hwang et al. (2018) Experimental Dermatology 27: 1304-1308”
Anti-inflammatory drug CP002
[Target] IKK kinase complex, the core element of the NF-kB pathways
[Dual inhibitor] Inhibits both canonical and non-canonical signaling pathways
[Target Disease] Inflammatory Bowel Disease (IBD) / Rheumatoid Arthritis / Psoriasis
[PoC verification in vivo] evaluate drug efficacy by TDD / IV route of administration
[Toxicity] completed both intravenous and transdermal toxicity test
[Side effects] completed Off-target effect analysis (eurofins)
Anticancer drug
[Target] tubulin (Microtubule-depolymerizing agents)
[Drug Resistance] overcome the major limitations of anticancer drugs in clinical use
[Target Disease] Skin and Colorectal Cancers
[PoC verification in vivo] evaluate drug efficacy by TDD / IV route of administration
[Toxicity] completed both intravenous and transdermal toxicity test
[Publications] “Hwang et al. (2017) PLOS ONE 12(3): e0173311”
